Request for Free Sample

Table Of Contents

1. Introduction

 1.1 Market Definition & Scope

 1.2 Research Assumptions & Abbreviations

 1.3 Research Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size By Test Type

  2.3.2 Market Size By End User

  2.3.3 Market Size By Type

 2.4 Market Share & Bps Analysis By Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

  3.4.1 Raw Material Suppliers

  3.4.2 Manufacturers

  3.4.3 Distributors/Suppliers

  3.4.4 Customers/End-Users

 3.5 Industry Life Cycle Assessment

 3.6 Parent Market Overview

 3.7 Market Risk Assessment

4. Statistical Insights & Trends Reporting

4.1 Pricing Analysis & Cost Structure

  4.1.1 Pricing Models: Per-test pricing, bundled diagnostic packages, insurance reimbursement-based pricing, subscription screening programs

  4.1.2 Average Cost Metrics: Cost variation across PSA tests, imaging, and biopsy procedures

  4.1.3 Cost Structure Breakdown: Reagents, imaging equipment, laboratory processing, personnel, reporting systems

  4.1.4 Price Benchmarking by Test Type: Blood tests, imaging diagnostics, biopsy procedures

  4.1.5 Forecasted Pricing Trends: Shift toward value-based diagnostics and multi-marker testing panels

4.2 Testing Volume & Screening Metrics

  4.2.1 Test Volume Metrics: Number of prostate cancer diagnostic tests conducted annually

  4.2.2 Screening Rate Metrics: Percentage of eligible male population undergoing screening

  4.2.3 Early Detection Metrics: Share of cases diagnosed at early stages

  4.2.4 Repeat Testing Metrics: Frequency of follow-up and confirmatory tests

  4.2.5 Population Coverage Metrics: Screening reach across age groups

4.3 Diagnostic Modality Metrics

  4.3.1 PSA Testing Metrics: Adoption of prostate-specific antigen blood tests

  4.3.2 Imaging Metrics: Use of MRI, ultrasound, and PET scans

  4.3.3 Biopsy Metrics: Number and type of biopsy procedures performed

  4.3.4 Molecular Diagnostics Metrics: Adoption of genomic and biomarker-based tests

  4.3.5 Liquid Biopsy Metrics: Growth of non-invasive diagnostic methods

4.4 Accuracy & Clinical Performance Metrics

  4.4.1 Sensitivity Metrics: Detection rate of prostate cancer cases

  4.4.2 Specificity Metrics: Ability to differentiate cancer from benign conditions

  4.4.3 False Positive/Negative Metrics: Diagnostic error rates

  4.4.4 Diagnostic Turnaround Time Metrics: Time from test to result delivery

  4.4.5 Risk Stratification Metrics: Accuracy in staging and grading cancer severity  

5. Prostate Cancer Diagnostics Market Segmental Analysis & Forecast, By Test Type, 2022–2035, Value (Usd Billion)

5.1 Introduction

 5.2 Preliminary Tests

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022–2035

 5.2.3 PSA Tests

 5.2.4 Free PSA Test

 5.2.5 Total PSA Test

 5.2.6 Other Preliminary Tests

 5.3 Confirmatory Tests

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022–2035

 5.2.3 Pca3 Test

 5.2.4 Trans-Rectal Ultrasound

 5.2.5 Biopsy Test

6. Prostate Cancer Diagnostics Market Segmental Analysis & Forecast, By End User, 2022–2035, Value (Usd Billion)

    6.1 Introduction

 6.2 Hospitals

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022–2035

 6.3 Outpatient Facilities

 6.4 Home Care

 6.5 Research & Manufacturing

7. Prostate Cancer Diagnostics Market Segmental Analysis & Forecast, By Type, 2022–2035, Value (Usd Billion)

    7.1 Introduction

 7.2 Adenocarcinoma

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022–2035

 7.3 Interstitial Cell Carcinoma

 7.4 Other

8. Prostate Cancer Diagnostics Market Segmental Analysis & Forecast By Region, 2022–2035, Value (Usd Billion)

8.1 Introduction

8.2 North America

 8.2.1 Key Trends

 8.2.2 Prostate Cancer Diagnostics Market Size & Forecast, By Test Type, 2022–2035

 8.2.3 Prostate Cancer Diagnostics Market Size & Forecast, By End User, 2022–2035

 8.2.4 Prostate Cancer Diagnostics Market Size & Forecast, By Type, 2022–2035

 8.2.5 Prostate Cancer Diagnostics Market Size & Forecast, By Country, 2022–2035

  8.2.5.1 USA

  8.2.5.2 Canada

8.3 Europe

 8.3.1 Key Trends

 8.3.2 Prostate Cancer Diagnostics Market Size & Forecast, By Test Type, 2022–2035

 8.3.3 Prostate Cancer Diagnostics Market Size & Forecast, By End User, 2022–2035

 8.3.4 Prostate Cancer Diagnostics Market Size & Forecast, By Type, 2022–2035

 8.3.5 Prostate Cancer Diagnostics Market Size & Forecast, By Country, 2022–2035

  8.3.5.1 Germany

  8.3.5.2 UK

  8.3.5.3 France

  8.3.5.4 Italy

  8.3.5.5 Spain

  8.3.5.6 Russia

  8.3.5.7 Poland

  8.3.5.8 Rest of Europe

8.4 Asia-Pacific

 8.4.1 Key Trends

 8.4.2 Prostate Cancer Diagnostics Market Size & Forecast, By Test Type, 2022–2035

 8.4.3 Prostate Cancer Diagnostics Market Size & Forecast, By End User, 2022–2035

 8.4.4 Prostate Cancer Diagnostics Market Size & Forecast, By Type, 2022–2035

 8.4.5 Prostate Cancer Diagnostics Market Size & Forecast, By Country, 2022–2035

  8.4.5.1 China

  8.4.5.2 India

  8.4.5.3 Japan

  8.4.5.4 South Korea

  8.4.5.5 Australia

  8.4.5.6 ASEAN Countries

  8.4.5.7 Rest of Asia-Pacific

8.5 Latin America

 8.5.1 Key Trends

 8.5.2 Prostate Cancer Diagnostics Market Size & Forecast, By Test Type, 2022–2035

 8.5.3 Prostate Cancer Diagnostics Market Size & Forecast, By End User, 2022–2035

 8.5.4 Prostate Cancer Diagnostics Market Size & Forecast, By Type, 2022–2035

 8.5.5 Prostate Cancer Diagnostics Market Size & Forecast, By Country, 2022–2035

  8.5.5.1 Brazil

  8.5.5.2 Argentina

  8.5.5.3 Mexico

  8.5.5.4 Colombia

  8.5.5.5 Rest of Latin America

8.6 Middle East & Africa

 8.6.1 Key Trends

 8.6.2 Prostate Cancer Diagnostics Market Size & Forecast, By Test Type, 2022–2035

 8.6.3 Prostate Cancer Diagnostics Market Size & Forecast, By End User, 2022–2035

 8.6.4 Prostate Cancer Diagnostics Market Size & Forecast, By Type, 2022–2035

 8.6.5 Prostate Cancer Diagnostics Market Size & Forecast, By Country, 2022–2035

  8.6.5.1 UAE

  8.6.5.2 Saudi Arabia

  8.6.5.3 Qatar

  8.6.5.4 Egypt

  8.6.5.5 South Africa

  8.6.5.6 Rest of Middle East & Africa

9. Competitive Landscape

 9.1 Key Players' Positioning

 9.2 Competitive Developments

  9.2.1 Key Strategies Adopted (%), By Key Players, 2025

  9.2.2 Year-Wise Strategies & Development, 2022–2025

  9.2.3 Number Of Strategies Adopted By Key Players, 2025

 9.3 Market Share Analysis, 2025

 9.4 Product/Service & Application Benchmarking

  9.4.1 Product/Service Specifications & Features By Key Players

  9.4.2 Product/Service Heatmap By Key Players

  9.4.3 Application Heatmap By Key Players

 9.5 Industry Start-Up & Innovation Landscape

9.6 Key Company Profiles

9.6.1 Abbott Laboratories

 9.6.1.1 Company Overview & Snapshot

 9.6.1.2 Product/Service Portfolio

 9.6.1.3 Key Company Financials

 9.6.1.4 SWOT Analysis

9.6.2 Siemens Healthineers

9.6.3 Roche Diagnostics

9.6.4 Hologic Inc.

9.6.5 Myriad Genetics Inc.

9.6.6 OPKO Health Inc.

9.6.7 Genomic Health (Exact Sciences Corporation)

9.6.8 MDxHealth

9.6.9 Beckman Coulter Inc.

9.6.10 Thermo Fisher Scientific Inc.

9.6.11 EDX Medical Group

9.6.12 bioMérieux SA

9.6.13 DiaSorin S.p.A.

9.6.14 QuidelOrtho Corporation

9.6.15 Becton Dickinson and Company

9.6.16 AstraZeneca plc

9.6.17 Pfizer Inc.

9.6.18 Novartis AG

9.6.19 EDAP TMS

9.6.20 Hitachi Ltd.

10. Analyst Recommendations

 10.1 SNS Insider Opportunity Map

 10.2 Industry Low-Hanging Fruit Assessment

 10.3 Market Entry & Growth Strategy

 10.4 Analyst Viewpoint & Suggestions On Market Growth

11. Assumptions

12. Disclaimer

13. Appendix

 13.1 List Of Tables

 13.2 List Of Figures